Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective

European Journal of Medicinal Chemistry

Volumn 45, Issue 4, 2010, Pages 1278-1286

  Abadi, Ashraf H ^a   Gary, Bernard D ^b   Tinsley, Heather N ^b,c   Piazza, Gary A ^b,c   Abdel Halim, Mohammad ^a  

^a German University in Cairo   (Egypt)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Carboline; PDE5 inhibition; Stereochemistry

Indexed keywords

2 BENZYL 6 (2 BROMOPHENYL) 2,3,6,7,12,12A HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 1,4 DIONE; 5 (2 BROMOPHENYL) 2 ETHYL 1 OXO 5,6,11,11A TETRAHYDRO 1H IMIDAZO[1',5':1,6]PYRIDO[3,4 B]INDOLE 3(2H) THIONE; 5 (2 BROMOPHENYL) 2 ETHYL 5,6,11,11A TETRAHYDRO 1H IMIDAZOL[1',5':1,6]PYRIDO[3,4 B]INDOLE 1,3(2H) DIONE; 6 (2 BROMOPHENYL) 2 BUTYL 2,3,6,7,12,12A HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 1,4 DIONE; 6 (2 BROMOPHENYL) 2 ETHYL 2,3,6,7,12,12A HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 1,4 DIONE; 6 (2 BROMOPHENYL) 2 METHYL 2,3,6,7,12,12A HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 1,4 DIONE; ANTINEOPLASTIC AGENT; CYCLIC GMP; METHYL 1 (2 BROMOPHENYL) 2 (2 CHLOROACETYL) 2,3,4,9 TETRAHYDRO 1H BETA CARBOLINE 3 CARBOXYLATE; METHYL 1 (2 BROMOPHENYL) 2,3,4,9 TETRAHYDRO 1H BETA CARBOLINE 3 CARBOXYLATE; PHOSPHODIESTERASE V INHIBITOR; TADALAFIL; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; COLON ADENOCARCINOMA; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR MODEL; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY; TUMOR GROWTH;

CARBOLINES; CELL DIVISION; COLONIC NEOPLASMS; HT29 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PHOSPHODIESTERASE INHIBITORS; SPECTROPHOTOMETRY, INFRARED; STEREOISOMERISM;

EID: 77349119224     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.10.046     Document Type: Article

References (16)

1. Lugnier C. Pharmacol. Ther. 109 (2006) 366-398
2. Bender A.T., and Beavo J.A. Pharmacol. Rev. 58 (2006) 488-520
3. Frajese G.V., and Pozzi F. J. Endocrinol. Invest. 28 (2005) 45-50
4. Piazza G.A., Thompson W.J., Pamukcu R., Alila H.W., Whitehead C.M., Liu L., Fetter J., Gresh Jr. W.E., Klein-Szanto A.J., Farnell D.R., Eto I., and Grubbs C.J. Cancer Res. 61 (2001) 3961-3968
5. Zhu B., Vemavarapu L., Thompson W.J., and Strada S.J. J. Cell. Biochem. 94 (2005) 336-350
6. Thompson W.J., Piazza G.A., Li H., Liu L., Fetter J., Zhu B., Sperl G., Ahnen D., and Pamukcu R. Cancer Res. 60 (2000) 3338-3342
7. Liu L., Li H., Underwood T., Lloyd M., David M., Sperl G., Pamukcu R., and Thompson W.J. J. Pharmacol. Exp. Ther. 299 (2001) 583-592
8. Donodoni A., and Perrone D. Org. Synth. 10 (2004) 320
9. Ungemach F., Soerens D., Weber R., Dipierro M., Campos O., Mokry P., and Cook J.M. J. Am. Chem. Soc. 102 (1980) 6976-6984
10. Sandrin J., Soerens D., and Cook J.M. Heterocycles 4 (1976) 1249-1255
11. Sunder-Plassmann N., Sarli V., Gartner M., Utz M., Seiler J., Huemmer S., Mayer T.U., Surrey T., and Giannis A. Bioorg. Med. Chem. 13 (2005) 6094-6111
12. Daugan A., Grondin P., Ruault C., Le Monnier de Gouville A.C., Coste H., Kirilovsky J., Hyafil F., and Labaudiniere R. J. Med. Chem. 46 (2003) 4525-4532
13. Lopez-Rodrlguez M.L., Morcillo M.J., Garrido M., Benhamtu B., Perez P., and de la Campa J.G. J. Org. Chem. 59 (1994) 1583-1585
14. Lopez Rodriguez M.L., Morcillo M.J., Benito F., Benhamu B., Fernandez E., Garrido M., and Orensanz L. Chem. Pharm. Bull. (Tokyo) 42 (1994) 2108-2112
15. Daugan A., Grondin P., Ruault C., Le Monnier de Gouville A.C., Coste H., Linget J.M., Kirilovsky J., Hyafil F., and Labaudiniere R. J. Med. Chem. 46 (2003) 4533-4542
16. MOE, Chemical Computing Group Inc.: Montreal, Available at: http://www.chemcomp/com.